Radman. Pfizer today announced the sale of their capsugel unit this monday morning. Though this is a drug delivery system division, it's a bit different than PSDV's platform. Pfizer is getting good money for capsugel. They do improve the balance sheet.Will they move into PSDV's delivery system? They are too different. I'd like to see a greater partnership on the biosilican platform with Pfizer. That would be HUGE! Pfizer got 2.5BIl for Capsugel. That could buy PSDV 2500 times. If there is something cooking inside PSDV regarding takeover, I think they'd do it before FDA ruling on Illuvien. The forward P/E on PSDV is mid single digits. It isn't getting any cheaper. Look at the volume.